Uncategorized
J&J pushes dual-antibody IBD therapy into Phase 3 despite mid-stage fails
Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative colitis.